Back to Archived News
Chemokine Therapeutics Announces Issuance of U.S. Patent
Thursday, July 03, 2008
Vancouver, British Columbia -- Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that it has been granted U.S. Patent No. 7,378,098.
Patent No. 7,378,098 entitled "CXC Chemokine Receptor 4 Agonist Peptides" is related to treatment of patients in need of bone marrow or stem cell transplantation. This patent is based on evidence that treatment with SDF-1 chemokine analog prevents reduction of normal bone marrow stem cells and restores white blood cells, which reduce susceptibility to infections in cancer patients following chemotherapy treatment.
"This patent strengthens the foundation for our work with our drug candidate CTCE-0214, for hematogical support; mobilization of stem cells and white blood cells into circulation, which is currently in Phase I development," said Dr. Donald Wong, Vice President, Drug Development.
About Chemokine Therapeutics Corp. (TSX:CTI)(OTCBB:CHKT)
Chemokine Therapeutics is a product-focused biotechnology company developing drug candidates in the field of chemokines. Chemokines are a class of signaling proteins that play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.
Back to Archived News
